You are here: Home > Products > Cervical Cancer Biom...

Cervical Cancer Biomarker Assay

CDx, short for “Cervical Cancer Diagnostics", provides specific and sensitive biomarker assays for oncogenic HPV causing high-grade precancerous cervical lesions. These assays are based on immunohistochemical methods. The reagent kits can be used on cytology specimens.

  • Cytology Immunocytochemistry (CDx-ICC)
    CDx-ICC reagent kit is an immunocytochemistry (ICC) assay kit for the qualitative detection of the oncogenic protein antigen on cervical cytology preparations.
  • Pathology Immunohistochemistry (CDx-IHC)
    CDx-IHC reagent kit is an immunohistochemistry (IHC) assay kit for the qualitative detection of the oncogenic protein expression in tumor or tissue section specimens.
  • CDx-ICC Plus
    CDx-ICC Plus is developed to detect the HPV oncogenic protein biomarker and a proliferation index protein for more precise and sensitive detection of high-grade precancerous cervical lesions.

Cervical Cancer

Cervical cancer is the second most common malignant tumor in women worldwide. There are about 520,000 new cases and more than 270,000 such cancer-associated deaths every year. In low-income countries, it is the most common cause of cancer death in women.

About 70% of cervical cancers occur in developing countries, where the lack of screening is the main reason of high mortality in cervical cancer. However, cervical cancer is highly preventable. Typically, the development of a precancerous lesion to cancer stage takes over 10 years or longer. Therefore, if the routine screening is implemented and pre-cancer found and treated early, the mortality rate can be reduced, and patient's outcome and 5-year disease-free survival can be significantly improved.
China has more than 400 million population of women in the age group 21 to 65-yr, who need to receive routine screening tests in order to reduce the cancer incidence rate.

HPV infections are very common and cause virtually all cervical cancer. However, only women with persistent infections from high-risk HPV (hr-HPV) strains and have developed high-grade precancerous disease should be treated.